A great lecture of Prof. Christian Rolfo at the #Fonicap consensus conference here at the International School of Medical Sciences in Erice 🇮🇹 Thanks for your invaluable contribution and support. International Society of Liquid Biopsy

WOW, listening to Christian Rolfo deliver an elegant lecture on liquid biopsy applications in #NSCLC in the timeless and magical setting of Erice, Sicily ... and in perfect Italian! 🇮🇹 IASLC International Society of Liquid Biopsy #Erice #Oncology #LiquidBiopsy

Thanks Drs Antonio Russo, rossanaberardi , Santo e Carecca for the invitation to give the Keynote Lecture #FONICAP consensus on Lung Cancer Units in beautiful Erice, Sicily 🇮🇹 congrats for the initiative International Society of Liquid Biopsy UniPa Ohio State Medical Oncology #fondazioneEttoreMajorana

Correlation between treatments&outcomes of pts with EGFR-mutated NSCLC that transitioned into SCLC: an international retrospective study in ESMO Open. Poor outcomes despite treatment, primary EGFR mutation maintained upon transformation. esmoopen.com/article/S2059-…

📢 Big News from ISLB! The Journal of Liquid Biopsy is Now Indexed in Scopus 🎉 We’re proud to share that the Journal of Liquid Biopsy — the official journal of the International Society of Liquid Biopsy (ISLB) — has been accepted for indexing on the Scopus platform! This major

Excellent news!! Thanks Umberto Malapelle for your leadership and all the International Society of Liquid Biopsy executive board , team and members for the commitment! M JOSE SERRANO Lab (LB&Cancer Interception group) David Gandara ELO

SCLC transformation from EGFR+ NSCLC, outcomes & tx? ESMO Open: - 25pts: CT (n=12), CT+EGFR-TKI (n=5), CT+ICI (n=6), CT+ICI+TKI (n=1) - mPFS 2m; mOS 9m, similar across tx - mOS if transf >12m v <12m (31m vs 8m, p<0.001) Chiara CATANIA OncoAlert #LCSM esmoopen.com/article/S2059-…

FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update! astrazeneca.com/media-centre/p…

Available JTO & JTO CRR - the 2024 IASLC Global Survey on Biomarker Testing. Majority (67%) reported most patients had biomarker testing (up from 39% in 2018) but 43% sometimes treated before results. Barriers: cost, time, tissue, access, awareness. jto.org/article/S1556-…

Get Featured at #ISLB25 - Submit Your Abstract Before September 8! We welcome abstracts covering a wide range of topics, including Advocacy and Regulatory Aspects of Liquid Biopsy, Clinical Applications, Clinical Trials Involving Liquid Biopsies, Composite Biomarkers, and much

Submit your abstract for #ISLB25 and join international experts in #liquidbiopsy this November in Orlando! Topics include early detection, composite biomarkers, clinical trials, and more. Deadline: Sept 8 | Publication & awards available. 🔗2025.islb.info/call-for-abstr…

Thrilled to share our new review in JITC: “Genetic drivers of tumor microenvironment and immunotherapy resistance in NSCLC” We focus on KEAP1, SMARCA4, and PTEN mutations and their role in immune evasion. Grateful to Christian Rolfo and my co-authors. 🔗 doi.org/10.1136/jitc-2…

Thanks Rodrigo Paredes, MD for sharing our review on Journal for ImmunoTherapy of Cancer ! A great team Alessandro Russo Giovanni Nigita, PhD Francesco Drago Roberto Borea, MD RolfoLab Society for Immunotherapy of Cancer The James Ohio State Medical Oncology

How to deal with KEAP1, SMARCA4, and PTEN mutations. A very hot topic in thoracic oncology and an emerging issue as their incidence is growing with the wider use of large NGS panels. A great team led by Prof Christian Rolfo. Congrats Rodrigo Paredes, MD! Journal for ImmunoTherapy of Cancer Christian Rolfo

Proud of this great review! Christian Rolfo, Rodrigo Paredes, MD Roberto Borea, MD, Alessandro Russo, Giovanni Nigita, PhD. 📄 @JITCancer 🔗 lnkd.in/eamekNdZ

Proud to be part of this review published in Journal for ImmunoTherapy of Cancer! We explored how KEAP1, SMARCA4 & PTEN mutations drive immune evasion & #immunotherapy resistance in #NSCLC. Rodrigo Paredes, MD Roberto Borea, MD Francesco Drago Alessandro Russo Christian Rolfo RolfoLab Link ➡️ shorturl.at/Q7pf9

Proud to share aur review on #liquidbiopsy in #urological #cancers . sciencedirect.com/science/articl…. Umberto Malapelle International Society of Liquid Biopsy OncoAlert 4oncommunity

RET+ NSCLC tumors commonly express MET and TROP2, with MET expression higher than in RET-wild-type controls. ja.ma/3IIm954 Alessandro Russo